8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2002

BIOJECT MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

Oregon
(State or other jurisdiction
of incorporation) 0-15360
(Commission
File Number) 93-1099680
(IRS Employer
Identification No.)

7620 S.W. Bridgeport Road, Portland, OR
(Address of principal executive offices) 97224
(Zip Code)

Registrant’s telephone number, including area code: (503) 639-7221

No Change
(Former name or former address, if changed since last report)

TABLE OF CONTENTS

	Item 5. Other Events
	Item 7. Financial Statements and Exhibits
SIGNATURE
EXHIBIT INDEX
Exhibit 99.1

Item 5. Other Events

     Attached to this Form 8-K as Exhibit 99.1 and incorporated into this Form 8-K by reference is the company’s press release dated February 26, 2002 announcing that Amgen Inc. has given notice to the company of its election not to pursue further development of Iject and B2000 devices.

Item 7. Financial Statements and Exhibits

     (c)  Exhibits.

     99.1 Press release dated February 26, 2002.

1

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     Dated: February 27, 2002.

BIOJECT MEDICAL TECHNOLOGIES, INC.
By:	/s/ Christine M. Farrell
	Christine M. Farrell Controller and Secretary

2

EXHIBIT INDEX

Exhibit	Description
99.1	Press release dated February 26, 2002.

EX-99.1 3 v79519ex99-1.htm EXHIBIT 99.1

EXHIBIT 99.1

BIOJECT ANNOUNCES THAT AMGEN ELECTS NOT TO PURSUE DEVELOPMENT AND
COMMERCIALIZATION UNDER LICENSING AGREEMENTS

Amgen Retains Options to Other Indications

     PORTLAND, OR, February 26, 2002 — Bioject Medical Technologies, Inc. (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, today announced that Amgen Inc. has given notice to the Company of its election not to pursue further development of Iject and B2000 devices. Amgen cited internal business reasons for its decision to halt development efforts. Amgen has not terminated its agreements with Bioject and still holds options to further license the technologies for certain other undisclosed indications.

     “We are disappointed at this unexpected news,” said Jim O’Shea, Chairman, President and CEO of Bioject. “Although this is a setback, we have the strongest pipeline of potential biotech and pharmaceutical partners in the history of the Company. We will continue to actively develop our technology and pursue licensing agreements with these companies.”

     The Company will conduct a conference call on Wednesday, February 27, 2002 at 9:00 a.m. Eastern Standard Time. Investors can access the call by dialing 1-800-388-8975. The conference call will be webcast and can be accessed through the Bioject website at www.bioject.com.

     Bioject Medical Technologies Inc., based in Portland Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The company is focused on developing mutually beneficial agreements with leading pharmaceutical and biotechnology companies.

     This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that its current strategic relationships will not develop into a long-term revenue producing relationship and uncertainties related to Bioject’s dependence on the continued performance of strategic partners and technology, product development, and regulatory risks involved in developing marketable products. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. Readers of this press release are referred to the company’s filings with the Securities and Exchange Commission,

including the company’s Reports on Form 10-K and Form 10-Qs for further discussions of factors which could affect future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The company assumes no obligation to update forward-looking statements if conditions or management’s estimates or opinions should change.

For more information on Bioject, visit: http://www.bioject.com

# # #

-----END PRIVACY-ENHANCED MESSAGE-----

EX-99.1

Exhibit 99.1